Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases

The performance of the interferon gamma release assays (IGRAs) and tuberculin skin test (TST) was reviewed retrospectively in patients with psoriasis, inflammatory musculoskeletal diseases, or miscellaneous inflammatory conditions. The study was carried out over a 22-month period using 109 records of patients with psoriasis (n = 21), musculoskeletal disease (n = 74), or other inflammatory conditions (n = 14). Forty-four (48%) of 109 patients were on immunosuppressive therapy and 38/109 (35%) on systemic glucocorticoid therapy. The agreement between the IGRAs was substantial (κ = 0.71) whilst that between the IGRAs and TST was low (κ = 0.32). Logistic regression models revealed that IGRAs associated with risk factors for latent tuberculosis infection better than TST. TST was influenced by age, BCG vaccination, sex, and glucocorticoid therapy. We found that IGRAs performed equally well with low level of indeterminate results (1-2%). IGRAs were superior to TST because the latter was influenced by BCG-vaccination status and immunosuppressive therapy.

[1]  N. Pollock,et al.  Low yield of chest radiography in a large tuberculosis screening program. , 2010, Radiology.

[2]  J. Kaldor,et al.  Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  S. Schreiber,et al.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement , 2010, European Respiratory Journal.

[4]  L. Pusa,et al.  Effector memory T-cells dominate immune responses in tuberculosis treatment: antigen or bacteria persistence? , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  K. Marten,et al.  Comparison of two interferon-γ release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases , 2010, Annals of the rheumatic diseases.

[6]  J. Himberg,et al.  Assessment of Imprecision in Gamma Interferon Release Assays for the Detection of Exposure to Mycobacterium tuberculosis , 2010, Clinical and Vaccine Immunology.

[7]  N. Inanç,et al.  Agreement Between Quantiferon-TB Gold Test and Tuberculin Skin Test in the Identification of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis , 2009, The Journal of Rheumatology.

[8]  D. Yoo,et al.  Positive Conversion of Tuberculin Skin Test and Performance of Interferon Release Assay to Detect Hidden Tuberculosis Infection During Anti-Tumor Necrosis Factor Agent Trial , 2009, The Journal of Rheumatology.

[9]  J. Saurat,et al.  Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon‐γ release assay vs. tuberculin skin test , 2009, The British journal of dermatology.

[10]  N. Milman,et al.  Comparison of Screening Procedures for Mycobacterium tuberculosis Infection Among Patients with Inflammatory Diseases , 2009, The Journal of Rheumatology.

[11]  K. Winthrop,et al.  Preventing and treating biologic-associated opportunistic infections , 2009, Nature Reviews Rheumatology.

[12]  M. Cerinic,et al.  QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases , 2009, European Respiratory Journal.

[13]  T. McDonnell,et al.  Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[14]  T. Tuuminen,et al.  IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland , 2009, BMC Research Notes.

[15]  Madhukar Pai,et al.  Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.

[16]  H. Soini,et al.  Feasibility of commercial interferon-gamma-based methods for the diagnosis of latent Mycobacterium tuberculosis infection in Finland, a country of low incidence and high bacille Calmette-Guérin vaccination coverage. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  P. Villiger,et al.  Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay , 2007, Annals of the rheumatic diseases.

[18]  D. Furst,et al.  Problems encountered during anti-tumour necrosis factor therapy. , 2006, Best practice & research. Clinical rheumatology.

[19]  J. Ledingham,et al.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). , 2005, Rheumatology.

[20]  J. Bathon,et al.  Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases , 2004, Journal of intensive care medicine.

[21]  D. Furst,et al.  Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents , 2002, Annals of the rheumatic diseases.

[22]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[23]  K. A. Hale.  Tuberculin skin test. Proper technique and interpretation. , 1985, Postgraduate medicine.